TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBD
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Low-grade NMIBC
Conditions
Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, FGFR3 Gene Fusions
Trial Timeline
Jun 27, 2025 → Sep 1, 2028
NCT ID
NCT06995677About TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBD
TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBD is a phase 2 stage product being developed by Tyra Biosciences for Low-grade NMIBC. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06995677. Target conditions include Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06995677 | Phase 2 | Recruiting |
Competing Products
13 competing products in Low-grade NMIBC
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 52 |
| Everolimus | Novartis | Phase 2 | 52 |
| MEK162, MEK inhibitor; oral + Physician's choice chemotherapy | Pfizer | Phase 3 | 76 |
| Fludarabine Phosphate (Fludara) + Rituximab | Sanofi | Phase 2 | 51 |
| rituximab | Biogen | Phase 3 | 74 |
| Tovorafenib | Ipsen | Phase 1 | 30 |
| Tovorafenib | Day One Biopharmaceuticals | Phase 2 | 47 |
| Tovorafenib + Chemotherapeutic Agent | Day One Biopharmaceuticals | Phase 3 | 72 |
| DAY101 | Day One Biopharmaceuticals | Phase 1 | 28 |
| Tovorafenib | Day One Biopharmaceuticals | Pre-clinical | 18 |
| rhuFlt3L/CDX-301 + Poly-ICLC | Celldex Therapeutics | Phase 1/2 | 36 |
| combined therapy with rh-ES and CV | Brain Biotech | Phase 2 | 44 |
Other Products from Tyra Biosciences
TYRA-300 0.125 mg/kg + TYRA-300 0.25 mg/kg + TYRA-300 0.375 mg/kg + TYRA-300 0.50 mg/kgPhase 2
47
Dabogratinib (TYRA-300) 60mg + Dabogratinib (TYRA-300) 80mg + Dabogratinib (TYRA-300) TBDPhase 2
47
TYRA-300Phase 1/2
36
TYRA-430Phase 1
28
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles + Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cyclesPhase 1
28